Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter L Anderson

Showing results (101-110 of 271) with videos related to

Pageof 28
Sort By:
Antimicrobial Agents and Chemotherapy|October 6, 2010
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteersJennifer J Kiser, J Brock Bumpass, Amie L Meditz, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 25, 2021
Pharmacokinetics of oral antimycobacterials and dosing guidance for Mycobacterium avium complex treatment in cystic fibrosisStacey L Martiniano, Brandie D Wagner, Laney Brennan, et al.
The Lancet. HIV|September 10, 2022
Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe: a secondary analysis of the HPTN 082 randomised controlled trialJennifer Velloza, Deborah Donnell, Sybil Hosek, et al.
AIDS Research and Human Retroviruses|July 27, 2018
Short Communication: Bioequivalence of Tenofovir and Emtricitabine After Coencapsulation with the Proteus Ingestible SensorMustafa E Ibrahim, Kristina M Brooks, José R Castillo-Mancilla, et al.
Antimicrobial Agents and Chemotherapy|March 7, 2012
Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudineJoseph E Rower, Amie Meditz, Edward M Gardner, et al.
AIDS Research and Human Retroviruses|October 21, 2014
Short communication: Tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected womenJose R Castillo-Mancilla, Kristina Searls, Patricia Caraway, et al.
Frontiers in Cellular and Infection Microbiology|May 8, 2023
A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravirAndrea R Thurman, Louise A Ouattara, Nazita Yousefieh, et al.
Polymers|March 26, 2022
Development and Evaluation of Nanoparticles-in-Film Technology to Achieve Extended In Vivo Exposure of MK-2048 for HIV PreventionXin Tong, Sravan Kumar Patel, Jing Li, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 24, 2022
Genital Inflammation Is Not Associated With Decreased Vaginal Tenofovir Concentrations in Women Taking Oral PrEPSheldon Morris, Mackenzie Cottrell, Stephen A Rawlings, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 29, 2020
Frequency and Predictors of Tenofovir-diphosphate Detection Among Young Kenyan Women in a Real-world Pre-exposure Prophylaxis Implementation ProgramJillian Pintye, John Kinuthia, Felix Abuna, et al.
Pageof 28

Showing results (101-110 of 271) with videos related to

Sort By:
Pageof 28
Antimicrobial Agents and Chemotherapy|October 6, 2010
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteersJennifer J Kiser, J Brock Bumpass, Amie L Meditz, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 25, 2021
Pharmacokinetics of oral antimycobacterials and dosing guidance for Mycobacterium avium complex treatment in cystic fibrosisStacey L Martiniano, Brandie D Wagner, Laney Brennan, et al.
The Lancet. HIV|September 10, 2022
Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe: a secondary analysis of the HPTN 082 randomised controlled trialJennifer Velloza, Deborah Donnell, Sybil Hosek, et al.
AIDS Research and Human Retroviruses|July 27, 2018
Short Communication: Bioequivalence of Tenofovir and Emtricitabine After Coencapsulation with the Proteus Ingestible SensorMustafa E Ibrahim, Kristina M Brooks, José R Castillo-Mancilla, et al.
Antimicrobial Agents and Chemotherapy|March 7, 2012
Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudineJoseph E Rower, Amie Meditz, Edward M Gardner, et al.
AIDS Research and Human Retroviruses|October 21, 2014
Short communication: Tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected womenJose R Castillo-Mancilla, Kristina Searls, Patricia Caraway, et al.
Frontiers in Cellular and Infection Microbiology|May 8, 2023
A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravirAndrea R Thurman, Louise A Ouattara, Nazita Yousefieh, et al.
Polymers|March 26, 2022
Development and Evaluation of Nanoparticles-in-Film Technology to Achieve Extended In Vivo Exposure of MK-2048 for HIV PreventionXin Tong, Sravan Kumar Patel, Jing Li, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 24, 2022
Genital Inflammation Is Not Associated With Decreased Vaginal Tenofovir Concentrations in Women Taking Oral PrEPSheldon Morris, Mackenzie Cottrell, Stephen A Rawlings, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 29, 2020
Frequency and Predictors of Tenofovir-diphosphate Detection Among Young Kenyan Women in a Real-world Pre-exposure Prophylaxis Implementation ProgramJillian Pintye, John Kinuthia, Felix Abuna, et al.
Pageof 28